Wellcome Trust, Agilent, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vanderbilt University, ArcticDx, Cancer Research Technology | GenomeWeb
Wellcome Trust Genotyping Study Using Agilent Arrays
Agilent Technologies said this week that the Wellcome Trust Case Control Consortium will use the firm’s custom-made, whole-genome copy number variation microarrays in the next phase of the genetic variation study.
Agilent is the third company to announce that the WTCCC is using its arrays for the second phase of the project. Previously, Illumina and Affymetrix both announced their technologies are being employed by researchers in the study.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.